Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3029314rdf:typepubmed:Citationlld:pubmed
pubmed-article:3029314lifeskim:mentionsumls-concept:C0019351lld:lifeskim
pubmed-article:3029314lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3029314lifeskim:mentionsumls-concept:C0598312lld:lifeskim
pubmed-article:3029314lifeskim:mentionsumls-concept:C0086243lld:lifeskim
pubmed-article:3029314lifeskim:mentionsumls-concept:C0733689lld:lifeskim
pubmed-article:3029314pubmed:dateCreated1987-4-20lld:pubmed
pubmed-article:3029314pubmed:abstractTextIt has been recently shown that VP-16-213, a semi-synthetic derivative of podophyllotoxin, inhibits the function of mammalian DNA topoisomerase II. In the present study, we examined the effects of VP-16-213 on the replication of herpes simplex virus type 2 (HSV-2). The compound did not inhibit the synthesis of early viral polypeptides at concentrations at which viral DNA synthesis was strongly suppressed, but induced double-strand breaks in newly synthesized HSV DNA. Electron microscopic examination of treated cells revealed the presence of a number of capsids with empty or partial cores. The level of topoisomerase II activity remained unaltered after infection, and all attempts to isolate VP-16-213-resistant mutants of HSV-2 have failed in spite of extensive efforts. It is suggested therefore that the mode of action of VP-16-213 may be inhibition of viral DNA synthesis by impairing the function of host cell topoisomerase II.lld:pubmed
pubmed-article:3029314pubmed:languageenglld:pubmed
pubmed-article:3029314pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3029314pubmed:citationSubsetIMlld:pubmed
pubmed-article:3029314pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3029314pubmed:statusMEDLINElld:pubmed
pubmed-article:3029314pubmed:monthMarlld:pubmed
pubmed-article:3029314pubmed:issn0022-1317lld:pubmed
pubmed-article:3029314pubmed:authorpubmed-author:NishiyamaYYlld:pubmed
pubmed-article:3029314pubmed:authorpubmed-author:YoshidaSSlld:pubmed
pubmed-article:3029314pubmed:authorpubmed-author:YamamotoNNlld:pubmed
pubmed-article:3029314pubmed:authorpubmed-author:ShimokataKKlld:pubmed
pubmed-article:3029314pubmed:authorpubmed-author:MaenoKKlld:pubmed
pubmed-article:3029314pubmed:authorpubmed-author:FujiokaHHlld:pubmed
pubmed-article:3029314pubmed:authorpubmed-author:TsurumiTTlld:pubmed
pubmed-article:3029314pubmed:issnTypePrintlld:pubmed
pubmed-article:3029314pubmed:volume68 ( Pt 3)lld:pubmed
pubmed-article:3029314pubmed:ownerNLMlld:pubmed
pubmed-article:3029314pubmed:authorsCompleteYlld:pubmed
pubmed-article:3029314pubmed:pagination913-8lld:pubmed
pubmed-article:3029314pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3029314pubmed:meshHeadingpubmed-meshheading:3029314-...lld:pubmed
pubmed-article:3029314pubmed:meshHeadingpubmed-meshheading:3029314-...lld:pubmed
pubmed-article:3029314pubmed:meshHeadingpubmed-meshheading:3029314-...lld:pubmed
pubmed-article:3029314pubmed:meshHeadingpubmed-meshheading:3029314-...lld:pubmed
pubmed-article:3029314pubmed:meshHeadingpubmed-meshheading:3029314-...lld:pubmed
pubmed-article:3029314pubmed:meshHeadingpubmed-meshheading:3029314-...lld:pubmed
pubmed-article:3029314pubmed:meshHeadingpubmed-meshheading:3029314-...lld:pubmed
pubmed-article:3029314pubmed:meshHeadingpubmed-meshheading:3029314-...lld:pubmed
pubmed-article:3029314pubmed:year1987lld:pubmed
pubmed-article:3029314pubmed:articleTitleEffects of the epipodophyllotoxin VP-16-213 on herpes simplex virus type 2 replication.lld:pubmed
pubmed-article:3029314pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3029314pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3029314lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3029314lld:pubmed